Marlyn J Mayo

List of Publications by Year
in descending order

48 papers	4,439 citations	218381 26 h-index	205818 48 g-index
51 all docs	51 docs citations	51 times ranked	3184 citing authors

#	Article	IF	Citations
1	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International, 2022, 42, 112-123.	1.9	31
2	Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1012-1013.	3.6	34
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
4	Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?. Hepatology, 2022, 76, 518-531.	3.6	17
5	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 2022, 77, 353-364.	1.8	36
6	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	2.4	30
7	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100191.	2.6	10
8	High Neutrophilâ€“Lymphocyte Ratio and Delta Neutrophilâ€“Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Digestive Diseases and Sciences, 2021, , 1.	1.1	8
9	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	2.4	17
10	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology, 2020, 72, 671-722.	3.6	473
11	Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Metaâ€Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology, 2020, 72, 753-769.	3.6	30
12	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.2	74
13	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. Clinical Liver Disease, 2020, 15, 1-2.	1.0	13
14	Managing the Symptoms and Complications of Cholestasis. Clinical Liver Disease, 2020, 15, 120-124.	1.0	6
15	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	6.1	28
16	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	2
17	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019, 69, 394-419.	3.6	507
18	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary Pharmacology and Therapeutics, 2019, 50, 1127-1136.	1.9	66

#	Article	IF	Citations
19	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
20	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	1.8	148
21	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatology Communications, 2019, 3, 365-381.	2.0	58
22	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. Journal of Hepatology, 2019, 70, 483-493.	1.8	124
23	Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures. Current Hepatology Reports, 2018, 17, 143-151.	0.4	1
24	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.2	64
25	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	3.6	55
26	NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Hepatology Communications, 2018, 2, 1037-1050.	2.0	96
27	Updated Etiology and Significance of Elevated Bilirubin During Pregnancy: Changes Parallel Shift in Demographics and Vaccination Status. Digestive Diseases and Sciences, 2017, 62, 517-525.	1.1	6
28	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proofâ€ofâ€concept study. Hepatology, 2016, 64, 189-199.	3.6	101
29	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	6.1	139
30	The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites. American Journal of the Medical Sciences, 2016, 351, 169-176.	0.4	20
31	Development of a Successful Scholarly Activity and Research Program for Subspecialty Trainees. American Journal of the Medical Sciences, 2015, 350, 222-227.	0.4	10
32	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	0.6	470
33	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	0.6	330
34	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
35	Primary biliary cirrhosis in 2014. Current Opinion in Gastroenterology, 2014, 30, 245-252.	1.0	24
36	Cholestatic Liver Disease Overlap Syndromes. Clinics in Liver Disease, 2013, 17, 243-253.	1.0	8

#	Article	IF	Citations
37	Management of autoimmune hepatitis. Current Opinion in Gastroenterology, 2011, 27, 224-230.	1.0	13
38	Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology, 2008, 48, 1549-1557.	3.6	167
39	Natural History of Primary Biliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 277-288.	1.0	37
40	Sertraline as a first-line treatment for cholestatic pruritus. Hepatology, 2007, 45, 666-674.	3.6	274
41	The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver International, 2006, 26, 187-196.	1.9	12
42	Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology, 2005, 42, 1184-1193.	3.6	112
43	Patients and patience: the pitfalls of primary biliary cirrhosis trials. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 552-553.	1.7	6
44	Primary biliary cirrhosis: the future. Clinics in Liver Disease, 2003, 7, 957-969.	1.0	5
45	Long-Term Efficacy of Sertraline As A Treatment for Cholestatic Pruritus in Patients With Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2003, 98, 2736-2741.	0.2	120
46	Extrahepatic Manifestations of Hepatitis C Infection. American Journal of the Medical Sciences, 2003, 325, 135-148.	0.4	133
47	Similar T-cell oligoclonality in antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Digestive Diseases and Sciences, 2001, 46, 345-351.	1.1	6
48	Non-PBC, Non-PSC autoimmune cholangiopathy. Current Treatment Options in Gastroenterology, 2000, 3, 121-131.	0.3	0